A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies

Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211050199. doi: 10.1177/20587384211050199.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependent enhancement phenomenon, better known as ADE. In this review, we provide an overview of SARS-CoV-2 infection as well as the immune response generated by the host. On the bases of this principle, we also describe what is known about the ADE phenomenon in various viral infections and its possible role as a limiting factor in the development of new vaccines and therapeutic strategies.PMID:34632844 | DOI:10.1177/20587384211050199
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

Int J Mol Med. 2022 Mar;49(3):33. doi: 10.3892/ijmm.2022.5088. Epub 2022 Jan 21.ABSTRACTThe pandemic caused by the severe acute respiratory syndrome coronavirus (SARS‑CoV‑2), responsible for coronavirus disease 2019 (COVID‑19) has posed a major challenge for global health. In order to successfully combat SARS‑CoV‑2, the development of effective COVID‑19 vaccines is crucial. In this context, recent studies have highlighted a high COVID‑19 mortality rate in patients affected by β‑thalassemia, probably due to their co‑existent immune deficiencies. In addition to a role in the severity of SARS‑CoV‑2 ...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for prev...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Xu Wang Li Wang COVID-19 has spread around the world and caused serious public health and social problems. Although several vaccines have been authorized for emergency use, new effective antiviral drugs are still needed. Some repurposed drugs including Chloroquine, Hydroxychloroquine and Remdesivir were immediately used to treat COVID-19 after the pandemic. However, the therapeutic effects of these drugs have not been fully demonstrated in clinical studies. In this paper, we found an antimalarial drug, Naphthoquine, showed good broad-spectrum anti-coronavirus activity. Naphthoquineinhibited HCoV-229E, HCoV-OC4...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSION: Our result indicates that these molecules may be further explored as promising candidates against SARS-CoV-2 or just simply suggested that Momordica charantia as one of the best food alternatives to be consumed during pandemic.PMID:35049440 | DOI:10.2174/1871526522666220113143358
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Source Type: research
Adar Poonawalla is no stranger to gambles. He owes his multibillion-dollar empire to a series of big bets that paid off handsomely. Cyrus Poonawalla, his father, made his own fortune on horses—and then multiplied it by making another bet in 1966: that he could make more money producing vaccines than he could on horse breeding and racing. He formed the Serum Institute of India (SII), which grew slowly for three decades, selling antivenoms and lifesaving vaccines for India. When Adar, then just 21, joined the company in 2001, he persuaded his father to dramatically ramp up production—wagering that they could fill...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized biztech2030 COVID-19 Davos feature Magazine overnight Special Project Source Type: news
Cancer is associated with excess morbidity and mortality from coronavirus disease 2019 (COVID-19) following infection by the novel pandemic coronavirus SARS-CoV-2. Vaccinations against SARS-CoV-2 have been rap...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Study protocol Source Type: research
As with any other ineradicable disease, prevention and treatment can be integrated into societyDelaying and preventing infection as much as possible through this pandemic was a worthwhile strategy. In early 2020, there were few treatments, limited testing and no vaccines. The costs of those lockdowns were big, but the effort to buy time paid off. In that time, science has transformed Covid from a deadly virus to a much less serious, nasty disease – one that is manageable at home, for the vast majority of those vaccinated. It has, largely, defanged it.But even as we have had success treating and preventing serious inf...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus Infectious diseases Health Medical research Microbiology Science UK news Vaccines and immunisation Source Type: news
TWiV reviews findings that increased fitness of the Omicron variant is due to immune evasion, not an increase in intrinsic transmissibility, and determination of infectious viral load in patients infected with wild type, Delta and Omicron viruses reveals lack of correlation with RNA loads determined by RT-PCR, similar levels of shedding among Delta and Omicron, […]
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation Long Covid monoclonal antibody pandemic SARS-CoV-2 vaccine vaccine booster variant of concern viruses Source Type: blogs
In this study, Metadichol® was found to be 270 times more potent an inhibitor of TMPRSS2 (EC50 = 96 ng/mL) than camostat mesylate (EC50 = 26000 ng/mL). Additionally, it inhibits ACE with an EC50 of 71 ng/mL, but it is a very weak inhibitor of ACE2 at an EC50 of 31 μg/mL. Furthermore, the live viral assay performed in Caco-2 cells revealed that Metadichol® inhibits SARS-CoV-2 replication at an EC90 of 0.16 μg/mL. Moreover, Metadichol® had an EC90 of 0.00037 μM, making it 2081 and 3371 times more potent than remdesivir (EC50 = 0.77 μM) and chloroquine (EC50 = 1.14 μM), respectively.PMID:35039793 | ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Chem Commun (Camb). 2022 Jan 18. doi: 10.1039/d1cc06520c. Online ahead of print.ABSTRACTThe coronavirus 2019 (COVID-19) pandemic is causing serious impacts in the world, and safe and effective vaccines and medicines are the best methods to combat the disease. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a key role in interacting with the angiotensin-converting enzyme 2 (ACE2) receptor, and is regarded as an important target of vaccines. Herein, we constructed the adjuvant-protein conjugate Pam3CSK4-RBD as a vaccine candidate, in which the N-terminal of the RBD was site-selectively oxidized by tra...
Source: Chemical Communications - Category: Chemistry Authors: Source Type: research
More News: Allergy & Immunology | Coronavirus | COVID-19 | Drugs & Pharmacology | Emergency Medicine | International Medicine & Public Health | Pandemics | Respiratory Medicine | SARS | Vaccines